Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948036 · ClinicalTrials.gov registry record · NA
A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
A NA study, sponsored by Posit Science Corporation.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02948036: Completed NA study, sponsored by Posit Science Corporation.
NCT02948036 is a NA study that has completed, run by Posit Science Corporation. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02948036, a NA study, has completed, sponsored by Posit Science Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale efficacy trial.
Primary Outcome
The Beck Depression Scale (BDI-II) is a self-report questionnaire that assesses depressive symptoms with a scoring range between 0-63.
Interventions
- OTHER Mobile-device, plasticity-based adaptive cognitive treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2023-05-11 |
| Phase | NA |
What the finished NCT02948036 record still lists
NCT02948036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Mobile-device, plasticity-based adaptive cognitive treatment is the first listed.
NCT02948036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02948036 about?
NCT02948036 is a clinical study titled "A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety". Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale efficacy trial.
What is the current status of trial NCT02948036?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-10-01. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT02948036?
The interventions under investigation include: Mobile-device, plasticity-based adaptive cognitive treatment (OTHER).
Who is sponsoring clinical trial NCT02948036?
This trial is sponsored by Posit Science Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02948036's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI